![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Professor Neil A. Williams
Professor Neil A. Williams, CSO at KWS BioTest, commented: “The recognition that some conventional and new cancer therapies can enhance recognition of cancer cells by the immune system points toward their use in combination with immunotherapies and heralds the possibility of improved outcomes for patients.
The assays, now validated at KWS, offer the potential to predict which drugs might work in this way, reducing the numbers of animals required in research and speeding up the development of new human treatments.”
Company:KWS BioTest
KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases. The addition of KWS BioTest enhances Charles River’s discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.
